A cure for type 1 diabetes? Beta cell replacement with zimislecel achieves insulin independence in early trial

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 diabetes within a year of treatment.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup